Late-onset invasive aspergillosis in organ transplant recipients in the current era

References

• Gavalda, J, Len, O, San Juan, R, , et al. for RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52–59.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37: S281–S292
   Google Scholar
• Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplan 2004; 4: 636–643
   PubMed Web of Science ®Google Scholar
• Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123–138
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46–52
   PubMed Web of Science ®Google Scholar
• Singh, N, Limaye, A, Safdar, N, , et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients (abstract M717). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16–19, December, 2005.
   Google Scholar
• Ascioglu S, Rex JH, Bennett JE, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89–99
   PubMed Web of Science ®Google Scholar
• Husain S, Alexander B, Munoz P, et al. Opportunistic mycelial fungi in organ transplant recipients; emerging importance of non-Aspergillus mycelial infections. Clin Infect Dis 2003; 37: 221–229
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715–2729
   PubMed Web of Science ®Google Scholar
• Cruz MC, Goldstein AL, Blankenship JR, et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO 2002; 21: 546–559
   PubMed Web of Science ®Google Scholar
• Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Ag Chemother 1997; 41: 156–161
   PubMedGoogle Scholar
• High KP, Washburn RG. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). J Infect Dis 1997; 175: 222–225
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Singh N, Miller JL, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and non-transplant patients. Antimicrob Ag Chemother 2004; 48: 4922–4925
   PubMed Web of Science ®Google Scholar
• Panackal AA, Dahlman A, Keil KT, et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 2003; 15: 1050–1053
   Google Scholar
• Mendez, R, Gonwa, T, Yang, HC, , et al. for the Prograf Study Group. A prospective, randomized trial of tacrolimus in combination with sirolimus of mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303–309.
   PubMed Web of Science ®Google Scholar
• Peddi VR, Jensik S, Pescovitz M, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130–136
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869–1875
   PubMed Web of Science ®Google Scholar
• Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307–313
   Google Scholar
• Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988; 10: S460–S467
   Google Scholar
• Laursen A, Mogensen S, Andersen H, Andersen P, Ellermann-Erksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001; 123: 239–246
   PubMed Web of Science ®Google Scholar